A systematic review of the effectiveness of interventions to enhance the healing of chronic ulcers of the foot in diabetes

Diabetes/Metabolism Research and Reviews

Volumn 24, Issue SUPPL. 1, 2008, Pages

  Hinchliffe, R J ^a,b   Valk, G D ^c   Apelqvist, J ^d   Armstrong, D G ^e   Bakker, K ^f   Game, F L ^b   Hartemann Heurtier, A ^g   Londahl M ^h   Price, P E ⁱ   van Houtum, W H ^j   Jeffcoate, William J ^b  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d MALMÖ UNIVERSITY   (Sweden)

^e ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^f IWGDF   (Netherlands)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h HELSINGBORG HOSPITAL   (Sweden)

ⁱ CARDIFF UNIVERSITY   (United Kingdom)

^j Infection and Immunology   (Netherlands)

more..

Author keywords

Diabetes; Diabetic foot; Dressings; Ulcer; Wound healing

Indexed keywords

ALGINIC ACID; BASIC FIBROBLAST GROWTH FACTOR; BECAPLERMIN; CARBOXYMETHYLCELLULOSE; EPIDERMAL GROWTH FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR; PHENYTOIN; PLACEBO; PLATELET DERIVED GROWTH FACTOR; POLYMER; PROSTAGLANDIN E2; RETINOIC ACID; SODIUM CHLORIDE;

AMPUTATION; ANTIMICROBIAL ACTIVITY; ANTISEPSIS; ARTERY DISEASE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMPRESSION THERAPY; CONFERENCE PAPER; DEBRIDEMENT; DIABETIC FOOT; EDEMA; ELECTROSTIMULATION THERAPY; FIBROBLAST CULTURE; FREEZE DRYING; HUMAN; HYDROGEL; HYPERBARIC OXYGEN; KERATINOCYTE; LOW LEVEL LASER THERAPY; MAGGOT THERAPY; MAGNETOTHERAPY; ORTHOPEDIC SURGERY; PLANTAR ULCER; PRIORITY JOURNAL; SKIN GRAFT; STEM CELL TRANSPLANTATION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ULCER; ULTRASOUND THERAPY; WOUND CARE; WOUND DRESSING; WOUND HEALING;

EID: 44949251001     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.825     Document Type: Conference Paper

References (85)

1. Jeffcoate WJ, Harding KG. Diabetic foot ulcers. Lancet 2003; 361: 1545-1551.
2. Boulton AJ, Vileikyte L, Ragnarson-Tennvall G, Apelqvist J. The global burden of diabetic foot disease. Lancet 2005; 366: 1719-1724.
3. Oyibo SO, Jude EB, Tarawneh I, et al. The effects of ulcer size and site, patient's age, sex and type and duration of diabetes on the outcome of diabetic foot ulcers. Diabet Med 2001; 18: 133-138.
4. Apelqvist J, Larsson J, Agardh CD. Long-term prognosis for diabetic patients with foot ulcers. J Intern Med 1993; 233: 485-491.
5. Jeffcoate WJ, Chipchase SY, Ince P, Game FL. Assessing the outcome of the management of diabetic foot ulcers using ulcer-related and person-related measures. Diabetes Care 2006; 29: 1784-1787.
6. Armstrong DG, Lavery LA, Harkless LB. Validation of a diabetic wound classification system. The contribution of depth, infection, and ischemia to risk of amputation. Diabetes Care 1998; 21: 855-859.
7. Lipsky BA, International consensus group on diagnosing and treating the infected diabetic foot. A report from the international consensus on diagnosing and treating the infected diabetic foot. Diabetes Metab Res Rev 2004; 20: S68-577.
8. Cavanagh PR, Lipsky BA, Bradbury AW, Botek G. Treatment for diabetic foot ulcers. Lancet 2005; 366: 1725-1735.
9. International Working Group on the Diabetic Foot. International Consensus on the Diabetic Foot, International Diabetes Federation, 2003.
10. Jeffcoate WJ, Price P, Harding KG, International Working Group on Wound Healing and Treatments for People with Diabetic Foot Ulcers. Wound healing and treatments for people with diabetic foot ulcers. Diabetes Metab Res Rev 2004; 20: S78-S89.
11. Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. Br Med J 2001; 323: 334-336.
12. Veves A, Falanga V, Armstrong DG, Sabolinski ML, Apligraf Diabetic Foot Ulcer Study. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care 2001; 24: 290-295.
13. Sherman RA. Maggot therapy fo treating idiabetic foot ulcers unresponsive to conventional therapy. Diabetes Care 2003; 26: 446-451.
14. Armstrong DG, Sala P, Short B, et al. Maggot therapy in "lower-extremity hospice" wound care. J. Am Podiatr Med Assoc 2005; 95: 254-257.
15. Saap LJ, Falanga V. Debridement performance index and its correlation with complete closure of diabetic foot ulcers. Wound Repair Regen 2002; 10: 354-359.
16. Steed DL, Donohoe D, Webster Lindsley L, Diabetic Ulcer Study Group. Effect of extensive debridement and treatment on the healing of diabetic foot ulcers. J Am Coll Surg 1996; 183: 61-64.
17. Apelqvist J, Ragnarson Tennvall G. Cavity foot ulcers in diabetic patients: a comparative study of cadexomer iodine ointment and standard treatment. An economic analysis alongside a clinical trial. Acta Derm Venereol 1996; 76: 231-235.
18. Apelqvist J, Larsson J, Stenstrom A. Topical treatment of necrotic foot ulcers in diabetic patients: a comparative trial of DuoDerm and MeZinc. Br J Dermatol 1990; 123: 787-792.
19. Donaghue VM, Chrzan JS, Rosenblum BI, Giurini JM, Habershaw GM, Veves A. Evaluation of a collagen-alginate wound dressing in the management of diabetic foot ulcers. Adv Wound Care 1998; 11: 114-119.
20. Lalau JD, Bresson R, Charpentier P, et al. Efficacy and tolerance of calcium alginate versus vaseline gauze dressings in the treatment of diabetic foot lesions. Diabetes Metab 2002; 28: 223-229.
21. Jensen JL, Seeley J, Gillin B. Diabetic foot ulcerations. A controlled, randomized comparison of two moist wound healing protocols: carrasyn Hydrogel Wound dressing and wet-to-moist saline gauze. Adv Wound Care 1998; 11: S1-S4.
22. Cangialosi CP Synthetic skin. A new adjunct in the treatment of diabetic ulcers. J Am Podiatry Assoc 1982; 72: 48-52.
23. Capasso VA, Munro BH. The cost and efficacy of two wound treatments. AORN J 2003; 77: 984-992.
24. Piaggesi A, Baccetti F, Rizzo L, Romanelli M, Navalesi R, Benzi L. Sodium carboxyl-methyl-cellulose dressings in the management of deep ulcerations of diabetic foot. Diabet Med 2001; 18: 320-324.
25. Tom WL, Peng DH, Allaei A, Hsu D, Hata TR. The effect of short-contact topical tretinoin therapy for foot ulcers in patients with diabetes. Arch Dermatol 2005; 141: 1373-1377.
26. Blackman JD, Senseng D, Quinn L, Mazzone T. Clinical evaluation of a semipermeable polymeric membrane dressing for the treatment of chronic diabetic foot ulcers. Diabetes Care 1994; 17: 322-325.
27. Muthukumarasamy MG, Sivakumar G, Manoharan G. Topical phenytoin in diabetic foot ulcers. Diabetes Care 1991; 14: 909-911.
28. Pai MR, Sitaraman N, Kotian MS. Topical phenytoin in diabetic ulcers: a double blind controlled trial. Indian J Med Sci 2001; 55: 593-599.
29. Piaggesi A, Schipani E, Campi F, et al. Conservative surgical approach versus non-surgical management for diabetic neuropathic foot ulcers: a randomized trial. Diabet Med 1998; 15: 412-417.
30. Armstrong DG, Rosales MA, Gashi A. Efficacy of fifth metatarsal head resection for treatment of chronic diabetic foot ulceration. J Am Podiatr Med Assoc 2005; 95: 353-356.
31. Armstrong DG, Lavery LA, Vazquez JR, et al. Clinical efficacy of the first metatarsophalangeal joint arthroplasty as a curative procedure for hallux interphalangeal joint wounds in patients with diabetes. Diabetes Care 2003; 26: 3284-3287.
32. Tan JS, Friedman NM, Hazelton-Miller C, Flanagan JP, File TM Jr. Can aggressive eatment of diabetic foot infections reduce the need for above-ankle amputation? Clin Infect Dis 1996; 23: 286-291.
33. Leslie CA, Sapico FL, Ginunas VJ, Adkins RH. Randomized controlled trial of topical hyperbaric oxygen for treatment of diabetic foot ulcers. Diabetes Care 1988; 11: 111-115.
34. Heng MC, Harker J, Bardakjian VB, Ayvazian H. Enhanced healing and cost-effectiveness of low-pressure oxygen therapy in healing necrotic wounds: a feasibility study of technology transfer. Ostomy Wound Manage 2000; 46: 52-60.
35. Faglia E, Favales F, Aldeghi A, et al. Adjunctive systemic hyperbaric oxygen therapy in treatment of severe prevalently ischemic diabetic foot ulcer. A randomized study. Diabetes Care 1996; 19: 1338-1343.
36. Kessler L, Bilbault P, Ortega F, et al. Hyperbaric oxygenation accelerates the healing rate of nonischemic chronic diabetic foot ulcers: a prospective randomized study. Diabetes Care 2003; 26: 2378-2382.
37. Doctor N, Pandya S, Supe A. Hyperbaric oxygen therapy in diabetic foot. J Postgrad Med 1992; 38: 112-114.
38. Abidia A, Laden G, Kuban G, et al. The role of hyperbaric oxygen therapy in ischaemic diabetic lower extremity ulcers: a doubleblind randomised-controlled trial. Eur J Vasc Endovasc Surg 2003; 25: 513-518.
39. Zamboni WA, Wong HP, Stephenson LL, Pfeifer MA. Evaluation of hyperbaric oxygen for diabetic wounds: a prospective study. Undersea Hyperb Med 1997; 24: 175-119.
40. McCallon SK, Knight CA, Valiulus JP, Cunningham MW, McCulloch JM, Farinas LP. Vacuum-assisted closure versus saline-moistened gauze in the healing of postoperative diabetic foot wounds. Ostomy Wound Manage 2000; 46: 28-32.
41. Eginton MT, Brown KR, Seabrook GR, Towne JB, Cambria RA. A prospective randomized evaluation of negative-pressure wound dressings for diabetic foot wounds. Ann Vasc Surg 2003; 17: 645-649.
42. Armstrong DG, Lavery LA, Diabetic Foot Study Consortium. Negative pressure wound therapy after partial diabetic foot amputation: a multicentre, randomised controlled trial. Lancet 2005; 366: 1704-1710.
43. Armstrong DG, Nguyen HC. Improvement in healing with aggressive edema reduction after debridement of foot infection in persons with diabetes. Arch Surg 2000; 135: 1405-1409.
44. Bennett NT, Schultz GS. Growth factors and wound healing: Part II. Role in normal and chronic wound healing. Am J Surg 1993; 166: 74-81.
45. Jude EB, Blakytny R, Bulmer J, Boulton AJ, Ferguson MW. Transforming growth factor-beta 1, 2, 3 and receptor type I and II in diabetic foot ulcers. Diabet Med 2002; 19: 440-447.
46. Lobmann R, Zemlin C, Motzkau M, Reschke K, Lehnert H. Expression of matrix metalloproteinases and growth factors in diabetic foot wounds treated with a protease absorbent dressing. J Diabetes Complications 2006; 20: 329-335.
47. Davidson NJ, Sowden JM, Fletcher J. Defective phagocytosis in insulin controlled diabetics: evidence for a reaction between glucose and opsonising proteins. J Clin Pathol 1984; 37: 783-786.
48. Wilson RM, Reeves WG. Neutrophil phagocytosis and killing in insulin-dependent diabetes. Clin Exp Immunol 1986; 63: 478-484.
49. Di Mauro C, Ossino AM, Trefiletti M, Polosa P, Beghe F. Lyophilized collagen in the treatment of diabetic ulcers. Drugs Exp Clin Res 1991; 17: 371-373.
50. Krupski WC, Reilly LM, Perez S, Moss KM, Crombleholme PA, Rapp JH. A prospective randomized trial of autologous platelet-derived wound healing factors for treatment of chronic nonhealing wounds: a preliminary report. J Vasc Surg 1991; 14: 526-532.
51. Steed DL, Goslen JB, Holloway GA, Malone JM, Bunt TJ, Webster MW. Randomized prospective double-blind trial in healing chronic diabetic foot ulcers. CT-102 activated platelet supernatant, topical versus placebo. Diabetes Care 1992; 15: 1598-1604.
52. Margolis DJ, Kantor J, Santanna J, Strom BL, Berlin JA. Effectiveness of platelet releasate for the treatment of diabetic neuropathic foot ulcers. Diabetes Care 2001; 24: 483-488.
53. Feng J, Du WH, Wang J. Clinical study of various growth factors on the improvement of impaired healing ulcers in patients with diabetic disease. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 1999; 13: 273-277.
54. Driver VR, Hanft J, Fylling CP, Beriou JM, Autologel Diabetic Foot Ulcer Study Group. A prospective, randomized, controlled trial of autologous platelet-rich plasma gel for the treatment of diabetic foot ulcers. Ostomy Wound Manage 2006; 52: 68-70.
55. Niezgoda JA, Van Gils CC, Frykberg RG, Hodde JP. Randomized clinical trial comparing OASIS Wound Matrix to Regranex Gel for diabetic ulcers. Adv Skin Wound Care 2005; 18: 258-266.
56. Steed DL, Diabetic Ulcer Study Group. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. J Vasc Surg 1995; 21: 71-78.
57. Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study. Diabetes Care 1998; 21: 822-827.
58. Robson MC, Payne WG, Garner WL, et al. Integrating the results of phase IV (post-marketing) clinical trial with four previous trials reinforces the position that Regranex (becaplermin) gel 0.01% is an effective adjunct to the treatment of diabetic foot ulcers. J Appl Res 2005; 5: 35-45.
59. Richard JL, Parer-Richard C, Daures JP, et al. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot. A pilot, randomized, double-blind, placebo-controlled study. Diabetes Care 1995; 18: 64-69.
60. Tsang MW, Wong WK, Hung CS, et al. Human epidermal growth factor enhances healing of diabetic foot ulcers. Diabetes Care 2003; 26: 1856-1861.
61. Afshari M, Larijani B, Fadayee M, et al. Efficacy of topical epidermal growth factor in healing diabetic foot ulcers. Therapy 2005; 2: 759-765.
62. Veves A, Sheehan P, Pham HT. A randomized, controlled trial of Promogran (a collagen/oxidized regenerated cellulose dressing) vs standard treatment in the management of diabetic foot ulcers. Arch Surg 2002; 137: 822-827.
63. Gough A, Clapperton M, Rolando N, Foster AV, Philpott-Howard J, Edmonds ME. Randomised placebo-controlled trial of granulocyte-colony stimulating factor in diabetic foot infection. Lancet 1997; 350: 855-859.
64. de Lalla F, Pellizzer G, Strazzabosco M, et al. Randomized prospective controlled trial of recombinant granulocyte colony-stimulating factor as adjunctive therapy for limb-threatening diabetic foot infection. Antimicrob Agents Chemother 2001; 45: 1094-1098.
65. Yonem A, Cakir B, Guler S, Azal OO, Corakci A. Effects of granulocyte-colony stimulating factor in the treatment of diabetic foot infection. Diabetes Obes Metab 2001; 3: 332-337.
66. Kastenbauer T, Hornlein B, Sokol G, Irsigler K. Evaluation of granulocyte-colony stimulating factor (Filgrastim) in infected diabetic foot ulcers. Diabetologia 2003; 46: 27-30.
67. Huang P, Li S, Han M, Xiao Z, Yang R, Han ZC. Autologous transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes. Diabetes Care 2005; 28: 2155-2160.
68. Viswanathan V, Mahesh U, Jayaraman M, Shina K, Ramachandram A. Beneficial role of granulocyte stimulating factor in foot infections in diabetic patients. J Assoc Phys India 2003; 51: 90-91.
69. Gentzkow GD, Iwasaki SD, Hershon KS, et al. Use of Dermagraft, a cultured human dermis, to treat diabetic foot ulcers. Diabetes Care 1996; 19: 350-354.
70. Naughton G, Mansbridge J, Gentzkow G. A metabolically active human dermal replacement for the treatment of diabetic foot ulcers. Artif Organs 1997; 21: 1203-1210.
71. Marston WA, Hanft J, Norwood P, Pollak R, Dermagraft Diabetic Foot Ulcer Study Group. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. Diabetes Care 2003; 26: 1701-1705.
72. Bayram Y, Deveci M, Imirzalioglu N, Soysal Y, Sengezer M. The cell based dressing with living allogenic keratinocytes in the treatment of foot ulcers: a case study. Br J Plast Surg 2005; 58: 988-996.
73. Puttirutvong P. Meshed skin graft versus split thickness skin graft in diabetic ulcer coverage. J Med Assoc Thai 2004; 87: 66-72.
74. Hanft JR, Surprenant MS. Healing of chronic foot ulcers in diabetic patients treated with a human fibroblast-derived dermis. Foot Ankle Surg 2002; 41: 291-299.
75. Baker LL, Chambers R, DeMuth SK, Villar F. Effects of electrical stimulation on wound healing in patients with diabetic ulcers. Diabetes Care 1997; 20: 405-412.
76. Peters EJ, Lavery LA, Armstrong DG, Fleischli JG. Electric stimulation as an adjunct to heal diabetic foot ulcers: a randomized clinical trial. Arch Phys Med Rehabil 2001; 82: 721-725.
77. Ennis WJ, Foremann P, Mozen N, Massey J, Conner-Kerr T, Meneses P. Ultrasound therapy for recalcitrant diabetic foot ulcers: results of a randomized, double-blind, controlled, multicenter study. Ostomy Wound Manage 2005; 51: 24-39.
78. Alvarez OM, Rogers RS, Booker JG, Patel M. Effect of noncontact normothermic wound therapy on the healing of neuropathic (diabetic) foot ulcers: an interim analysis of 20 patients. J Foot Ankle Surg 2003; 42: 30-35.
79. Szor J, Holewinski P. Lessons learned in research: an attempt to study the effects of magnetic therapy. Ostomy Wound Manage 2002; 48: 24-29.
80. Chiglashvili DS, Istomin DA. Complex treatment of patients with the diabetic foot. Klin Med (Mosk). 2004; 82: 66-69.
81. Bergin SM, Wraight P. Silver based wound dressings and topical agents for treating diabetic foot ulcers. Cochrane Database Syst Rev 2006; 1: CD005082.
82. Münter K-C, Beele H, Russel L, et al. Effect of a sustained silver-releasing dressing on ulcers with delayed healing: the CONTOP study. J Wound Care 2006; 15: 199-206.
83. Smith J. Debridement of diabetic foot ulcers. Cochrane Database Syst Rev 2002; 4: CD003556.
84. Eldor R. Raz I, Ben Yehuda A, Boulton AJ. New and experimental approaches to treatment of diabetic foot ulcers: a comprehensive review of emerging treatment strategies. Diabet Med 2004; 21: 1161-1173.
85. Cruciani M, Lipsky BA, Mengoli C, de Lalla F. Are granulocyte colony-stimulating factors beneficial in treating diabetic foot infections?: A meta-analysis. Diabetes Care 2005; 28: 454-460.